Aethlon Medical up as substance used in blood purifier device binds COVID variants

Aethlon Medical

02/05/2022 17:20

** Shares of medical device company Aethlon Medical Inc
 AEMD.O  rise 3.7% to $1.11
    ** Co says its proprietary GNA affinity resin was able to
bind seven clinically relevant SARS-CoV-2 variants in vitro
studies, including Delta and Omicron  urn:newsml:reuters.com:*:nPnbrXwk4a
    ** GNA affinity resin is key component of co's Hemopurifier,
an investigational device designed to remove viruses and
exosomes from blood
    ** Data published in bioRxiv
    ** Viral capture efficiency ranged from 53% to 89% for seven
COVID-19 variants tested - AEMD
    ** Stock down ~40.3% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))